Clinical Trials
3 trialsNCT07543172 2026-04-21
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
NCT04298606 2026-03-17
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT02955290 2025-11-10
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting